-
EP3796975
European procedure
Extract from the Register of European Patents
EP About this file: EP3796975
| EP3796975 - SULFONYLAMINOBENZAMIDE DERIVATIVES [Right-click to bookmark this link] | |||
| Former [2021/13] | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | ||
| [2022/43] | Status | No opposition filed within time limit Status updated on 05.07.2024 Database last updated on 02.11.2024 | |
| Former | The patent has been granted Status updated on 28.07.2023 | ||
| Former | Grant of patent is intended Status updated on 13.03.2023 | ||
| Former | Examination is in progress Status updated on 24.02.2023 | ||
| Former | Grant of patent is intended Status updated on 13.10.2022 | ||
| Former | Examination is in progress Status updated on 17.12.2021 | ||
| Former | Request for examination was made Status updated on 26.02.2021 | ||
| Former | The international publication has been made Status updated on 30.11.2019 | ||
| Former | unknown Status updated on 12.06.2019 | Most recent event Tooltip | 05.07.2024 | No opposition filed within time limit | published on 07.08.2024 [2024/32] | Applicant(s) | For all designated states OrsoBio, Inc. 2671 Marshall Drive Palo Alto, CA 94303 / US | [2023/03] |
| Former [2022/33] | For all designated states The Liver Company Inc. 2671 Marshall Drive Palo Alto, CA 94303 / US | ||
| Former [2021/13] | For all designated states GILEAD SCIENCES, INC. 333 Lakeside Drive Foster City California 94404 / US | Inventor(s) | 01 /
FARAND, Julie c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 / US | 02 /
KAPLAN, Joshua A. c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 / US | 03 /
NOTTE, Gregory c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 / US | 04 /
OLEN, Casey Lockwood 2221 Lake Road 7 Belmont, CA 94002 / US | 05 /
SANGI, Michael c/o Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 / US | 06 /
SPERANDIO, David 3779 Nathan Court Palo Alto, California 94303 / US | [2021/13] | Representative(s) | Marks & Clerk LLP 15 Fetter Lane London EC4A 1BW / GB | [2023/35] |
| Former [2021/13] | Nieuwenhuys, William Francis Marks & Clerk LLP 15 Fetter Lane London EC4A 1BW / GB | Application number, filing date | 19728290.8 | 17.05.2019 | [2021/13] | WO2019US32925 | Priority number, date | US201862674981P | 22.05.2018 Original published format: US 201862674981 P | [2021/13] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019226490 | Date: | 28.11.2019 | Language: | EN | [2019/48] | Type: | A1 Application with search report | No.: | EP3796975 | Date: | 31.03.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 28.11.2019 takes the place of the publication of the European patent application. | [2021/13] | Type: | B1 Patent specification | No.: | EP3796975 | Date: | 30.08.2023 | Language: | EN | [2023/35] | Search report(s) | International search report - published on: | EP | 28.11.2019 | Classification | IPC: | C07C311/08, C07C311/14, C07C311/21, C07C311/29, C07C311/39, C07C311/46, C07C317/14, C07D275/02, C07D257/04, C07D279/12, C07D305/06, C07D451/14, C07D205/04, C07D493/08, C07D295/26, C07D213/71, A61P1/16, A61P3/00, A61P3/10, A61K31/18 | [2022/43] | CPC: |
C07D335/02 (EP,KR,US);
C07C311/46 (EP,KR,US);
C07C323/25 (US);
A61K31/18 (US);
A61K31/351 (KR);
A61K31/382 (KR);
A61K31/541 (KR);
A61P1/16 (EP,KR,US);
C07B59/001 (EP);
C07C307/10 (EP);
C07C311/08 (EP,US);
C07C311/13 (EP,US);
C07C311/14 (EP,US);
C07C311/21 (EP,US);
C07C311/29 (EP,US);
C07C311/39 (EP,US);
C07C313/06 (US);
C07C317/14 (EP);
C07C317/18 (EP);
C07C317/48 (EP);
C07C323/12 (EP);
C07C323/30 (US);
C07C323/31 (US);
C07C381/00 (EP);
C07D205/04 (EP,US);
C07D207/48 (US);
C07D213/71 (EP);
C07D213/89 (US);
C07D231/18 (EP,US);
C07D233/20 (EP);
C07D235/00 (US);
C07D239/26 (EP,US);
C07D257/04 (EP,US);
C07D275/02 (EP,US);
C07D277/36 (EP,US);
C07D279/12 (EP,US);
C07D295/116 (US);
C07D295/26 (EP,KR);
C07D305/06 (EP);
C07D305/08 (US);
C07D309/08 (EP,KR,US);
C07D451/02 (US);
C07D451/14 (EP);
C07D493/08 (EP,US);
C07F9/5022 (US);
C07F9/5325 (EP);
C07B2200/05 (KR);
C07C2602/02 (EP);
C07C2602/38 (EP,KR);
C07C2602/42 (EP,KR);
C07C2602/44 (EP,KR);
C07C2602/50 (EP);
C07C2603/74 (EP);
C07C2603/90 (EP);
Y02E60/50 (EP)
(-)
|
| Former IPC [2021/13] | A61P1/16 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/13] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | SULFONYLAMINOBENZAMIDDERIVATE | [2022/43] | English: | SULFONYLAMINOBENZAMIDE DERIVATIVES | [2022/43] | French: | DÉRIVÉS SULFONYLAMINOBENZAMIDES | [2022/43] |
| Former [2021/13] | SULFINYLAMINOBENZAMID- UND SULFONYLAMINOBENZAMIDDERIVATE | ||
| Former [2021/13] | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | ||
| Former [2021/13] | DÉRIVÉS SULFINYLAMINOBENZAMIDE ET SULFONYLAMINOBENZAMIDE | Entry into regional phase | 22.12.2020 | National basic fee paid | 22.12.2020 | Designation fee(s) paid | 22.12.2020 | Examination fee paid | Examination procedure | 22.12.2020 | Examination requested [2021/13] | 22.12.2020 | Date on which the examining division has become responsible | 30.07.2021 | Amendment by applicant (claims and/or description) | 20.12.2021 | Despatch of a communication from the examining division (Time limit: M04) | 28.04.2022 | Reply to a communication from the examining division | 14.10.2022 | Communication of intention to grant the patent | 23.02.2023 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 14.03.2023 | Communication of intention to grant the patent | 24.07.2023 | Fee for grant paid | 24.07.2023 | Fee for publishing/printing paid | 24.07.2023 | Receipt of the translation of the claim(s) | Opposition(s) | 03.06.2024 | No opposition filed within time limit [2024/32] | Fees paid | Renewal fee | 13.05.2021 | Renewal fee patent year 03 | 25.05.2022 | Renewal fee patent year 04 | 26.05.2023 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HR | 30.08.2023 | RS | 30.08.2023 | SK | 30.08.2023 | [2024/25] |
| Former [2024/11] | HR | 30.08.2023 | |
| RS | 30.08.2023 | Cited in | International search | [X]WO0218335 (YAMANOUCHI PHARMA CO LTD [JP], et al); | [X]EP2865664 (BAMICHEM CO LTD [KR], et al); | [YA]WO2016081599 (UNIV RUTGERS [US]); | [YA]WO2017201313 (JIN SHENGKAN [US], et al); |